KR102598180B1 - 항-트랜스타이레틴 항체 - Google Patents

항-트랜스타이레틴 항체 Download PDF

Info

Publication number
KR102598180B1
KR102598180B1 KR1020177023749A KR20177023749A KR102598180B1 KR 102598180 B1 KR102598180 B1 KR 102598180B1 KR 1020177023749 A KR1020177023749 A KR 1020177023749A KR 20177023749 A KR20177023749 A KR 20177023749A KR 102598180 B1 KR102598180 B1 KR 102598180B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
ttr
delete delete
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177023749A
Other languages
English (en)
Korean (ko)
Other versions
KR20170106469A (ko
Inventor
유에 리우
타를로칸 에스. 니자
아비짓 채크라바티
제프리 엔. 히가키
Original Assignee
프로테나 바이오사이언시즈 리미티드
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테나 바이오사이언시즈 리미티드, 유니버시티 헬스 네트워크 filed Critical 프로테나 바이오사이언시즈 리미티드
Priority to KR1020237037602A priority Critical patent/KR102677203B1/ko
Publication of KR20170106469A publication Critical patent/KR20170106469A/ko
Application granted granted Critical
Publication of KR102598180B1 publication Critical patent/KR102598180B1/ko
Assigned to 노보 노르디스크 에이/에스 reassignment 노보 노르디스크 에이/에스 권리지분의 전부이전등록 Assignors: 네오토프 뉴로사이언스 리미티드
Assigned to 네오토프 뉴로사이언스 리미티드 reassignment 네오토프 뉴로사이언스 리미티드 권리지분의 전부이전등록 Assignors: 프로테나 바이오사이언시즈 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177023749A 2015-01-28 2016-01-28 항-트랜스타이레틴 항체 Active KR102598180B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237037602A KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562109002P 2015-01-28 2015-01-28
US62/109,002 2015-01-28
US201562266556P 2015-12-11 2015-12-11
US62/266,556 2015-12-11
PCT/IB2016/050415 WO2016120810A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037602A Division KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Publications (2)

Publication Number Publication Date
KR20170106469A KR20170106469A (ko) 2017-09-20
KR102598180B1 true KR102598180B1 (ko) 2023-11-03

Family

ID=55299694

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177023749A Active KR102598180B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체
KR1020237037602A Active KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237037602A Active KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Country Status (31)

Country Link
US (1) US20160251418A1 (https=)
EP (2) EP4134379A1 (https=)
JP (2) JP6748086B2 (https=)
KR (2) KR102598180B1 (https=)
CN (1) CN107406499B (https=)
AU (1) AU2016210888C1 (https=)
CA (1) CA2974912A1 (https=)
CL (2) CL2017001924A1 (https=)
CO (1) CO2017008476A2 (https=)
CU (1) CU24480B1 (https=)
DK (1) DK3250592T3 (https=)
EA (1) EA036080B1 (https=)
ES (1) ES2934656T3 (https=)
FI (1) FI3250592T3 (https=)
HR (1) HRP20221538T1 (https=)
HU (1) HUE060878T2 (https=)
IL (1) IL253633B (https=)
LT (1) LT3250592T (https=)
MX (1) MX394170B (https=)
PE (1) PE20180217A1 (https=)
PH (1) PH12017501318A1 (https=)
PL (1) PL3250592T3 (https=)
PT (1) PT3250592T (https=)
RS (1) RS63906B1 (https=)
SA (1) SA517382002B1 (https=)
SG (2) SG10202101763VA (https=)
SI (1) SI3250592T1 (https=)
TW (2) TWI786505B (https=)
UA (1) UA122142C2 (https=)
WO (1) WO2016120810A1 (https=)
ZA (1) ZA201705663B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
CU24731B1 (es) 2017-10-06 2025-01-15 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
AU2018345807B2 (en) 2017-10-06 2025-02-06 Novo Nordisk A/S Methods of detecting transthyretin
PE20211453A1 (es) * 2017-11-29 2021-08-05 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
WO2020094883A1 (en) 2018-11-09 2020-05-14 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
EP4121766A1 (en) 2020-03-18 2023-01-25 AL-S Pharma AG Misfolded sod1 assay
MX2022014223A (es) 2020-05-12 2023-04-14 Neurimmune Ag Terapia de combinacion para amiloidosis de la ttr.
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法
CN113845593B (zh) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 抗α-SMA蛋白单克隆抗体、细胞系及其应用
US20250019425A1 (en) * 2021-11-12 2025-01-16 Adrx, Inc. Transthyretin (ttr) monomer binding antibodies
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
AU2023364181A1 (en) * 2022-10-19 2025-04-03 Ibio, Inc. Chemokine receptor 8 (ccr8) antibodies
EP4619431A1 (en) 2022-11-15 2025-09-24 Neurimmune AG Methods for treating or preventing transthyretin-mediated amyloidosis
AU2024239150A1 (en) * 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
EP4713354A1 (en) 2023-05-19 2026-03-25 Neurimmune AG Novel immunotherapy for musculoskeletal disorders and conditions
AR134366A1 (es) 2023-11-15 2026-01-07 Neurimmune Ag Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina
AR134700A1 (es) 2023-12-15 2026-03-04 Novo Nordisk As Formulaciones líquidas estables
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2015010118A2 (en) 2013-07-19 2015-01-22 The University Of Texas Transthyretin amyloid-selective and polyreactive catabodies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
NZ513144A (en) 1999-02-05 2003-05-30 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
EP2808020A1 (en) 2006-04-21 2014-12-03 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Beta-Amyloid Pet Imaging Agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
NZ580043A (en) 2007-03-02 2012-04-27 Boehringer Ingelheim Pharma Improvement of protein production through increased expression of mutated start domain protein cert
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
FI20115165A0 (fi) * 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
AU2018345807B2 (en) 2017-10-06 2025-02-06 Novo Nordisk A/S Methods of detecting transthyretin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2015010118A2 (en) 2013-07-19 2015-01-22 The University Of Texas Transthyretin amyloid-selective and polyreactive catabodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PNAS, 제96권, 제6호, 제3108-3113면 (1999. 3. 16.)
Rejuvenation Research, 제17권, 제2호, 제97-104면 (2014. 4.)

Also Published As

Publication number Publication date
CN107406499A (zh) 2017-11-28
TWI786505B (zh) 2022-12-11
PT3250592T (pt) 2022-12-28
EP4134379A1 (en) 2023-02-15
CA2974912A1 (en) 2016-08-04
PH12017501318B1 (en) 2018-02-05
WO2016120810A1 (en) 2016-08-04
CO2017008476A2 (es) 2018-01-16
FI3250592T3 (fi) 2023-01-13
KR20170106469A (ko) 2017-09-20
SA517382002B1 (ar) 2021-11-25
JP2020185009A (ja) 2020-11-19
SG11201706124VA (en) 2017-08-30
TW201632554A (zh) 2016-09-16
JP2018506277A (ja) 2018-03-08
US20160251418A1 (en) 2016-09-01
SI3250592T1 (sl) 2023-03-31
PH12017501318A1 (en) 2018-02-05
CU20170097A7 (es) 2018-03-13
IL253633A0 (en) 2017-09-28
EP3250592A1 (en) 2017-12-06
HUE060878T2 (hu) 2023-04-28
PL3250592T3 (pl) 2023-06-19
CU24480B1 (es) 2020-03-04
AU2016210888C1 (en) 2022-06-02
JP6748086B2 (ja) 2020-09-02
SG10202101763VA (en) 2021-04-29
HRP20221538T1 (hr) 2023-03-03
MX2017009806A (es) 2018-08-15
AU2016210888B2 (en) 2021-11-04
CL2022003027A1 (es) 2023-06-09
KR102677203B1 (ko) 2024-06-20
BR112017016330A2 (en) 2018-04-03
JP7028923B2 (ja) 2022-03-02
TWI718122B (zh) 2021-02-11
RS63906B1 (sr) 2023-02-28
PE20180217A1 (es) 2018-01-31
AU2016210888A1 (en) 2017-08-10
EP3250592B1 (en) 2022-10-05
IL253633B (en) 2021-06-30
EA036080B1 (ru) 2020-09-23
ZA201705663B (en) 2018-08-29
KR20230156164A (ko) 2023-11-13
EA201791712A1 (ru) 2017-12-29
MX394170B (es) 2025-03-24
TW202124436A (zh) 2021-07-01
ES2934656T3 (es) 2023-02-23
UA122142C2 (uk) 2020-09-25
CN107406499B (zh) 2021-10-22
NZ733896A (en) 2024-11-29
DK3250592T3 (en) 2023-01-09
CL2017001924A1 (es) 2018-04-27
LT3250592T (lt) 2023-02-10

Similar Documents

Publication Publication Date Title
KR102598180B1 (ko) 항-트랜스타이레틴 항체
KR102649788B1 (ko) 항-트랜스타이레틴 항체
KR102619359B1 (ko) 항-트랜스타이레틴 항체
US10669330B2 (en) Anti-transthyretin antibodies
US11629185B2 (en) Anti-transthyretin antibodies
KR20200074956A (ko) 항-트랜스타이레틴 항체
US11267878B2 (en) Anti-transthyretin antibodies
JP2019532617A (ja) 抗トランスサイレチン抗体
HK1240247A1 (en) Anti‐transthyretin antibodies
HK1240247B (en) Anti‐transthyretin antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210127

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20221116

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230506

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230801

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231031

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231101

End annual number: 3

Start annual number: 1

PG1601 Publication of registration